Clinical Trials Browser

Interventional × Afatinib × CNS × Clear all

NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 1 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT05432518 2025-04-25

Pilot Trial for Treatment of Recurrent Glioblastoma

Phase EARLY_PHASE1 Recruiting

Glioblastoma, Recurrence

NCT02768337 2024-01-31

CamBMT1

Phase 1/2 Terminated

BreastCNSThoracic

Brain Neoplasms, Breast Neoplasms, Lung Neoplasms

NCT02423525 2022-03-10

Safety Study of Afatinib for Brain Cancer

Phase 1 Completed

Astrocytoma, Brain Neoplasms, Glioblastoma, Meningioma, Oligodendroglioma, Meningeal Carcinomatosis

NCT04158947 2020-05-12

HER2BAT

Phase 2 Unknown

Brain Neoplasms

NCT00977431 2019-02-18

Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform

Phase 1 Completed

36 enrolled 16 charts

Glioblastoma

NCT00727506 2017-08-15

BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma

Phase 2 Completed

151 enrolled 42 charts

Glioma